Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer

• Wen-Yen Huang,

  Affiliations Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

  ⨯
• Ching-Liang Ho,

  Affiliation Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Chia-Cheng Lee,

  Affiliation Division of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Cheng-Wen Hsiao,

  Affiliation Division of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Chang-Chieh Wu,

  Affiliation Division of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Shu-Wen Jao,

  Affiliation Division of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Jen-Fu Yang,

  Affiliation Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Cheng-Hsiang Lo,

  Affiliation Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

  ⨯
• Jia-Hong Chen

  * E-mail: ndmc_tw.tw@yahoo.com.tw

  Affiliations Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University

  ⨯